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LETTERS TO THE EDITOR 1227(see Fig E3, A-C). Heterodimerization of PAR1 and PAR4 is pre-
cedented, providing a mechanism for thrombin bound to PAR1
through exosite 1 to cleave PAR4 (which cannot bind) more effi-
ciently.4 The formation of a ternary complex would thus render
ROS generation sensitive to antagonism of both receptors and
imply that the main effector of Der p 1–stimulated ROS produc-
tion might be PAR4, which is notably associated with epithelial-
mesenchymal transition in airway cells.
Hitherto, PAR1 and PAR4 have not been considered activatable
by group 1 HDM allergens,2 but in revealing the Der p 1–depen-
dent cleavage of prothrombin we have identified their canonical
activation with subsequent intracellular ROS formation via ATP
release. Extracellular ATP is elevated in asthma, which is note-
worthy because it stimulates dendritic cells and triggers the
release of IL-33, which is genetically linked to asthma suscepti-
bility and a key activator of cytokine production by iH2 nuocytes.
5
Thrombin is present in airway surface liquid in asthma at levels
sufficiently elevated to drive cell proliferation and is also
increased following respiratory virus infection.6 Although it is
generally assumed that these changes are associated with tissue
repair following inflammation, our data implicate thrombin-
mediated signaling as both an innate strategic initiator and an
effector-perpetuator of allergic sensitization through its direct
generation by inhaled Der p 1.
That the Toll-like receptor 3 ligand poly i:c operates ROS
generation through a mechanism that converges with Der p 1
signaling at pannexons is interesting because interactions be-
tween allergens and respiratory viruses precipitate exacerbations
of asthma and allergy-polarizing transcription factors are redox
sensitive. PAR1 contributes to the pathogenicity of influenza A,7
PAR1 and Toll-like receptor 3 are both upregulated by respiratory
virus infections,8 ATP promotes TH2 immunity, and P2X7 expres-
sion is upregulated in asthma.5 It will therefore be of interest to
investigate the operational role of pannexons as a signaling nexus
in allergic sensitization and the triggering of disease
exacerbations.
The sensitivity of Toll-like receptor 3–mediated activation to
argatroban or PAR1 antagonists (see Fig E2, E-F) suggests that
events downstream of pannexon opening involve the endogenous
activation of thrombin, creating a cyclical process. These findings
reveal a surprising primary trigger for thrombin production that
further emphasize its contribution to inflammatory lung re-
sponses. Although an oral thrombin inhibitor, albeit with
bioavailability and protein binding which may preclude signifi-
cant airway access from the systemic circulation, has only mod-
erate improving effect on HDM-induced pathology in a murine
model,9 our data suggest that it would be of interest to explore
similar effects of ADIs, especially as these molecules have been
optimized with the pharmaceutical credentials for inhaled
delivery.
Additional information is available (see this article’s Methods,
Results, and References sections in the Online Repository at
www.jacionline.org).
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tifies micro-RNA–based biomarker
panel for Kawasaki diseaseTo the Editor:
Kawasaki disease (KD) is an autoimmune disease preferen-
tially attacking children younger than 5 years. Symptoms of KD
include fever for at least 5 days, oral mucosal inflammation,
nonsupportive conjunctivitis, lymphadenopathy, edema of the
extremities, and a polymorphous rash. If left untreated, almost
20% to 25% of the patients with KDmay develop severe coronary
artery aneurysms, making KD the leading cause of acquired
heart disease in young children in developed countries.1 The
successful detection of KD within the first 10 days of fever onset
followed by treatment with high-dose intravenous immuno-
globulin can greatly reduce the risk of severe coronary artery
lesions.1-3 Therefore, early and successful detection is critical
for treating KD.
TABLE I. Demographic data of subjects in this study
Characteristic FC (N 5 70) KD (N 5 50) P value
Sex: male, n (%) 33 (47.1) 25 (50) .853
Clinical features Diagnosis:
Upper respiratory tract infection (28)
Lower respiratory tract infection (27)
Gastroenteritis (3)
Urticaria (3)
Septic arthritis (2)
Dengue fever (1)
Scarlet fever (1)
Systemic lupus erythematosus (1)
Henoch-Sch€onlein purpura (1)
Atopic dermatitis (1)
Acute hepatitis (1)
Urinary tract infection (1)
Bilateral conjunctivitis: 46 (92%)
Oral mucosal change: 43 (86%)
Lymphadenopathy: 23 (46%)
Swelling/peeling of hands and feet: 36 (72%)
Rash: 43 (86%)
CALs: 15 (30%)
IVIG resistance: 2 (4%)
We collected the FC set subjects when the patients without KDhad fever. In addition, all subjects, including FC andKD, did not suffer from other diseases except for the onesmentioned
in this table. CALs were defined if any of the following findings were seen on 2-dimensional echocardiography: coronary artery internal diameter of greater than 3 mm in children
younger than 5 years, or greater than 4mm in children older than 5 years, or if the internal diameter of a segment wasmore than 1.5 times greater than that of an adjacent segment. Of the
50 patients with KD included in this study, 15 patients (30%) had positive CAL findings on 2-dimensional echocardiography and 2 patients (4%) were IVIG resistant.
CAL, Coronary artery lesion; IVIG, intravenous immunoglobulin.
FIG 1. MiRNA profiles in the training set. A,We randomly selected the 12 FC and 12 KD RNA samples from
the training set, followed by evenly pooling RNAs to form 2 pooled FC and 2 pooled KD libraries. The pooled
RNA libraries were subject to NGS to determine miRNA expression profiles. The heat map showed that the
pooled FC and KD libraries were distinguishable on the basis of miRNA expression profiles. Only the
miRNAs with more than 100 transcripts per million in either library and with greater than 1.5-fold change
were included for clustering analysis. B, We used qPCR to validate the expression profiles by NGS in all
RNA samples from the training set. Among the 10 illustrated miRNAs, 8 are significantly differentially
expressed between control and disease samples. The C and D prefixes in the labels of X-axis denote FC
and KD samples, respectively. ****P < .0001, ***P < .001, **P < .01, and *P < .05. The miRNA expression
abundances were presented in the unit of DCt with U6 as the internal control.
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developed.4 Therefore, the detection of KD still mainly relies on
the judgment of clinical physicians based on patients’ symptoms.
However, infectious diseases by pathogens may also result in
symptoms similar to those of KD, making it difficult to accurately
diagnose KD and leading to a delay in optimal and timely
treatment of KD.
Previous studies have shown that bloodmiRNAs can be used as
disease biomarkers.5-7 So, we enrolled 70 fever control (FC,
denoting patients without KD with fever) and 50 subjects with
KD (see this article’s Methods section in the Online Repository
at www.jacionline.org). Among them, 37 FC and 31 KD subjects
comprised the training set, used for developing the KD biomarkerpanel with next-generation sequencing (NGS) and/or quantitative
PCR (qPCR) assays. The remaining 33 FC and 19 KD subjects
comprised the blind test set, used for examining the performance
of the developed KD biomarker panel. Table I shows that the most
prevalent diagnosis of FC subjects was upper or lower respiratory
tract infection (28 and 27 patients, respectively). In patients with
KD, bilateral conjunctivitis, oral mucosa changes, and rash were
the most prevalent clinical features.
We extracted RNA samples from white blood cells (see this
article’s Methods section in the Online Repository). Then, we had
2 pooled FC and 2 pooled KD RNA libraries sequenced with
Illumina NGS platform, followed by miRSeq8 analysis for
determining micro (mi)-RNA expression profiles (see Table E1
FIG 2. ROC curve of the Support Vector Machine (SVM) classificationmodel and the interface of KDP. A, The
ROC curve shows the high performance of the SVM classification model. B, We released the KDP to the
academic society for free use. The users have to prepare the miRNA expression profile and present it in
the format as demonstrated in the tutorial instruction. By submitting the expression data, KDP will finish
the analysis jobs and return the analysis results within 1 minute. ROC, Receiver operating characteristic.
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According to miRSeq result, almost 80% of the initial reads
belonged to clean read, the sequence read with 39 adaptor
recognized and trimmed. In addition, most clean reads were
22-nt long (see Fig E1 in this article’s Online Repository at
www.jacionline.org), reflecting high performance of the sample
preparation procedures and implying the dominance of miRNAs,
which was proven by Fig E2 in this article’s Online Repository at
www.jacionline.org.
To examine whether the FC and KD samples were distinguish-
able on the basis of miRNA expression profiles, we conducted
clustering analysis. The heat map showed that the duplicated
libraries had similar and consistent patterns (Fig 1, A). Moreover,
there were more than 20 miRNAs able to distinguish FC fromKD
samples so that they can serve as biomarkers of KD.
For further validation with qPCR in the training set, 37 FC and
31 KD subjects, we selected 10 miRNAs with NGS abundance
larger than 1000 transcript per million in at least 1 library andwith
average fold change larger than 1.25 between FC and KD
libraries. As a result, we observed 10 miRNAs whose expression
preferences by qPCR were consistent with the ones by NGS (see
Table E2 in this article’s Online Repository at www.jacionline.
org). Fig 1, B, demonstrates that 8 of the 10 examined
miRNAs were significantly differentially expressed. Although
the remaining 2 miRNAs were not statistically significant, the
expression preferences can be observed.
Because males have a higher KD incidence rate than do
females, we further investigated whether the 10 miRNAs are
significantly differentially expressed between male and female
subjects, causing bias when served as a disease biomarker.
Although the expression of hsa-miR-941 is significant between
males and females (P 5 .0282), the difference between control
and disease is much more significant than that between sex
(P 5 6.7319 3 10207 vs P 5 .0282). The expressions of the
remaining 9 biomarker miRNAs were not sex specific. Therefore,we used the DCt values of the 10 miRNAs to develop a KD
biomarker panel, training a Support Vector Machine (SVM)
classification model, and diagnosing KD.
SVM is a machine learning algorithm and is good in dealing
with binary classification problems, treatment versus control or
disease versus normal.9 We used the DCt values of the 10 panel
miRNAs (Table E2) to train the SVM classification model
with 5-fold cross-validation specified to eliminate overfitting
and underfitting. As shown in Fig 2, A, the final SVM
classification model has a sensitivity of 83.3% and a specificity
of 92.5%, leading to an overall accuracy of 87.9% and a 0.9
area under receiver operating characteristic (auROC) value.
An independent cohort, composed of 33 FC and 19 KD
subjects, was applied to conduct a blind test. We determined the
miRNA DCt values of the 52 blind test subjects (see Table E3 in
this article’s Online Repository at www.jacionline.org). After
SVMmodel alignment, 16 of the 19 KD samples were diagnosed
as KD and 27 of the 33 FC samples were diagnosed as not KD,
demonstrating a sensitivity of 84.20% and a specificity of
81.8%. The SVM performance examined with the blind test set
was similar to the one examined with the training set, reflecting
the robustness and reliability of the SVM classification model.
In addition, it reflected that the overfitting and underfitting
problems were slight in our SVM classification model.
To facilitate the early detection of KD, we built the Web-based
user-friendly interface, Kawasaki disease Detection Platform
(KDP, Fig 2, B), accessible via http://formosa3.nchc.org.
tw:50190/KDP/index.php. To detect KD, the physicians or
researchers may submit the DCt values of the 10 panel miRNAs
onto the KDP. KDP calls the SVM alignment and then
reports the detection result in both graphical (Fig 2, B) and
text formats (see Fig E3 in this article’s Online Repository at
www.jacionline.org). In summary, our biomarker panel provides
a useful tool for researchers and physicians, facilitating early
detection of KD.
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predicts clinical benefit from anti–
IL-13 in asthmaTo the Editor:
Asthma is the most prevalent chronic disease of children in
industrialized countries. However, the immunopathology of
asthma is most commonly described in adults in whom the
airways are characterized by heterogeneous eosinophilic airwayinflammation. In moderate-to-severe asthma in adults, biologic
therapies directed against type 2 inflammatory cytokines are
currently under development; meaningful clinical benefit from
these interventions is enriched in subjects selected on the basis of
noninvasive biomarkers of type 2-‘‘high’’ asthma, for example,
serum periostin and blood or sputum eosinophils.1
In a study of 277 pediatric subjects with asthma, serum
periostin and peripheral blood eosinophils were significantly
negatively correlated with age and serum periostin was
substantially elevated in pediatric patients with asthma compared
with adult patients with asthma.2 These data suggest that
factors other than type 2 inflammation may influence serum
periostin and blood eosinophil levels in children with asthma.
The ability of these biomarkers to predict clinical benefit
from type 2 pathway–directed therapies in pediatric asthma is
currently unknown. Therefore, alternative biomarkers of type 2
inflammation may need to be evaluated in children and
adolescents with asthma.
We hypothesized that gene expression correlated with
eosinophil count in asthma patients’ peripheral blood (1) would
be enriched for genes whose expression levels predict treatment
benefit from anti–IL-13 therapy, (2) would include genes whose
expression was independent of age, and (3) whose cellular origin
of expression is associated with type 2 inflammatory cells and/or
type 2 cytokine signaling. To develop an eosinophil-related gene
signature (ERGS), we evaluated genomewide transcript levels in
stabilized RNA extracted from peripheral blood from multiple
clinical studies of well-characterized patients with asthma. The
clinical characteristics of subjects with asthma included in this
analysis are summarized in Table E1 in this article’s Online
Repository at www.jacionline.org.
We assessed peripheral blood gene expression in 298 subjects
(12-75 years old) from the EXTRA study by microarrays
(see this article’s Methods section in the Online Repository at
www.jacionline.org). Although this study was not designed nor
powered to detect an elevation in serum periostin or blood
eosinophil count in adolescent (<18 years old, N 5 15) versus
adult (>_18 years old) patients with asthma, we observed median
elevations of 37 ng/mL periostin (P < .05) and 20 eosinophils
per mL (not statistically significant), respectively (see Fig E1 in
this article’s Online Repository at www.jacionline.org). Six
hundred twenty-five genes were significantly correlated with
blood eosinophil counts (adjusted P value < .05; 50 genes with
the lowest adjusted P value are tabulated in Table E2 in this
article’s Online Repository at www.jacionline.org). Regression
analysis (Fig 1, A) reveals a skewing toward genes that are
positively correlated with absolute blood eosinophil count,
suggesting that blood eosinophil count is an important source of
expression variation. CCL23, SIGLEC8, PTGDR2, CACNG6,
IDO1, and HSD3B7 were among the most positively
correlated genes with absolute blood eosinophil count (Fig 1, A;
Table E2; see Fig E2 in this article’s Online Repository at
www.jacionline.org) and selected as candidate genes for
subsequent assessment due to (1) minimal evidence of age
dependency across a wide range of age (12-75 years old;
Fig E2), (2) biological plausibility, and (3) technical robustness
of quantitative PCR assay development on a clinically amenable
assay platform, the COBAS system (data not shown). Using this
assay platform, we then characterized the expression of these
genes on the basis of their ability to predict eosinophilic airway
inflammation, blood eosinophil count, and clinical response to
